Get started
Veradermics, IncorporatedVeradermics, IncorporatedVeradermics, Incorporated

Veradermics, Incorporated

No trades
OverviewFinancialsNewsDocumentsCommunityTechnicalsForecastsETFs
Full chart
Full chart

Latest earnings


Last report date
May 12, 2026
Report period
Q1 2026
EPS
−1.16 USD
Revenue
0.00 USD

Key stats


Market capitalization
‪4.43 B‬ USD
Dividend yield (indicated)
—
Price to earnings Ratio (TTM)
—
Basic EPS (TTM)
—
Net income (FY)
‪−70.00 M‬ USD
Revenue (FY)
0.00 USD
Shares float
‪32.17 M‬
Beta (1Y)
−0.47

Employees


Employees (FY)
21
Revenue / Employee (1Y)
0.00 USD
Net income / Employee (1Y)
‪−3.33 M‬ USD

About Veradermics, Incorporated


Sector
Health Technology
Industry
Pharmaceuticals: Major
CEO
Reid Waldman
Website
veradermics.com
Headquarters
New Haven
Founded
2019
IPO date
Feb 4, 2026
IPO offer price
17.00 USD
Identifiers
3
ISIN US9229671048
CFI code
ESVUFR
Veradermics, Inc. is a late clinical-stage biopharmaceutical company. It focuses on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. The company was founded in 2019 and is headquartered in New Haven, CT.

Check out other big names from the same industry as MANE.

Financials


Performance
Revenue to profit conversion
Debt level and coverage
Earnings
Next:—

News



Technicals


Summarizing what the indicators are suggesting.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

Analyst rating


An aggregate view of professional's ratings.
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy
Neutral
SellBuy
Strong sellStrong buy
Strong sellSellNeutralBuyStrong buy

ETFs holding the stock


SCHA
Schwab U.S. Small-Cap ETF
Weight 0.05%
Market value ‪10.07 M‬
LFSC
F/m Emerald Life Sciences Innovation ETF
Weight 3.68%
Market value ‪3.77 M‬
JGRO
JPMorgan Active Growth ETF
Weight 0.04%
Market value ‪3.52 M‬
TOS
Twin Oak Strategic Solutions ETF
Weight 2.06%
Market value ‪3.18 M‬
FPX
First Trust US Equity Opportunities ETF
Weight 0.14%
Market value ‪2.01 M‬
JPGH
JPMorgan ETFS Ireland ICAV - JPM Active US Growth UCITS ETF
Weight 0.08%
Market value ‪337.95 K‬
JPGR
JPMorgan ETFS Ireland ICAV - JPM Active US Growth UCITS ETF
Weight 0.08%
Market value ‪337.95 K‬
JGRO
JPMorgan US Growth Active ETF Trust Units
Weight 0.08%
Market value ‪20.16 K‬
FPX
First Trust US Equity Opportunities UCITS ETF Accum Shs A USD
Weight 0.14%
Market value ‪17.45 K‬

Explore more ETFs 

Frequently asked questions


The current price of MANE is 99.72 USD — it has decreased by −5.99% in the past 24 hours. Watch Veradermics, Incorporated stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NYSE exchange Veradermics, Incorporated stocks are traded under the ticker MANE.
MANE stock has fallen by −7.56% compared to the previous week, the month change is a 32.91% rise, over the last year Veradermics, Incorporated has showed a 193.29% increase.
We've gathered analysts' opinions on Veradermics, Incorporated future price: according to them, MANE price has a max estimate of 138.00 USD and a min estimate of 120.00 USD. Watch MANE chart and read a more detailed Veradermics, Incorporated stock forecast: see what analysts think of Veradermics, Incorporated and suggest that you do with its stocks.
MANE reached its all-time high on May 6, 2026 with the price of 117.71 USD, and its all-time low was 32.00 USD and was reached on Feb 4, 2026. View more price dynamics on MANE chart.
See other stocks reaching their highest and lowest prices.
MANE stock is 8.46% volatile and has beta coefficient of −0.47. Track Veradermics, Incorporated stock price on the chart and check out the list of the most volatile stocks — is Veradermics, Incorporated there?
Yes, you can track Veradermics, Incorporated financials in yearly and quarterly reports right on TradingView.
Veradermics, Incorporated is going to release the next earnings report on Sep 2, 2026. Keep track of upcoming events with our Earnings Calendar.
MANE earnings for the last quarter are −1.16 USD per share, whereas the estimation was −0.64 USD resulting in a −82.16% surprise. The estimated earnings for the next quarter are −0.67 USD per share. See more details about Veradermics, Incorporated earnings.
Veradermics, Incorporated revenue for the last quarter amounts to 0.00 USD, matching the estimated figure, and no changes in revenue are expected for the next quarter.
MANE net income for the last quarter is ‪−27.23 M‬ USD, while the quarter before that showed ‪−21.85 M‬ USD of net income which accounts for 0.00% change. Track more Veradermics, Incorporated financial stats to get the full picture.
No, MANE doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of May 16, 2026, the company has 21 employees. See our rating of the largest employees — is Veradermics, Incorporated on this list?
Like other stocks, MANE shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Veradermics, Incorporated stock right from TradingView charts — choose your broker and connect to your account.